LLS

Cyclists Take On America's Most Beautiful Bike Ride In Support Of Blood Cancer Patients

Retrieved on: 
Wednesday, April 3, 2024
Diagnosis, Team In Training, Acute lymphoblastic leukemia, Bone marrow, University of Nevada, Reno, Leukemia & Lymphoma Society, Leukemia, Patient, SVP, Research, Perspiration, Cancer, University, RYE, Quality of life, LLS, Reader

RYE BROOK, N.Y., April 3, 2024 /PRNewswire/ -- Cyclists from across the country will help change the lives of blood cancer patients by gathering in Lake Tahoe on June 2, 2024 to participate in America's Most Beautiful Bike Ride. While working up a sweat and enjoying breathtaking views, riders' efforts will drive forward the work of The Leukemia & Lymphoma Society (LLS) to fund groundbreaking research, provide free patient support and assistance, and advocate on behalf of blood cancer patients and their families.

Key Points: 
  • In its efforts to reach and help all those impacted by a blood cancer diagnosis, LLS actively partners in communities across the country.
  • This year, LLS welcomes WVU Cancer Institute as America's Most Beautiful Bike's premier sponsor and new venue partner Tahoe Blue Event Center.
  • This year, America's Most Beautiful Bike Ride has chosen leukemia survivor Greg Carlson as the event's Honored Hero.
  • WHY: To support LLS and make an impact in the lives of all those affected by a blood cancer diagnosis.

Susan G. Komen® and Walgreens Mark 5 Years of Impact, Surpassing $37 Million in Cancer Support

Retrieved on: 
Monday, March 25, 2024
Health, Leukemia, Partnership, Patient, Research, Breast, Cancer, Equity, LLS, Social, Breast cancer, Nursing

CHICAGO, March 25, 2024 /PRNewswire/ -- Susan G. Komen®, the world's leading breast cancer organization and Walgreens announced today another milestone in the transformative five-year collaboration that has not only propelled groundbreaking research in breast cancer but has also significantly expanded access to essential breast health and breast cancer services, support and resources.. Throughout this multi-year partnership, Walgreens has contributed nearly $38 million to Komen and the Leukemia & Lymphoma Society to advance research for challenging-to-treat cancers and promote equitable access to care.

Key Points: 
  • With Walgreens' support, Susan G. Komen began serving patients directly through Komen's Patient Care Center in 2020, providing services like patient navigation and financial assistance to breast cancer patients nationwide through a telehealth model.
  • During the February 2024 "Care in Your Corner" campaign, Walgreens' customers demonstrated their generosity through in-store donations, contributing more than $5.4 million.
  • This collective effort has not only provided vital funds but has also opened new avenues for Susan G. Komen to extend support to individuals impacted by breast cancer.
  • "This year marks the culmination of five years of donations to Susan G. Komen and the Leukemia and Lymphoma Society.

Jasper Health and The Leukemia & Lymphoma Society® (LLS) Collaborate to Support Blood Cancer Patients

Retrieved on: 
Wednesday, March 13, 2024
Quality of life, Education, Patient, LLS, Bone marrow, Leukemia & Lymphoma Society, Cancer, Leukemia, Caregiver, Birth control

This collaboration aims to provide comprehensive support and resources to blood cancer patients and their caregivers throughout their cancer experience journey.

Key Points: 
  • This collaboration aims to provide comprehensive support and resources to blood cancer patients and their caregivers throughout their cancer experience journey.
  • Jasper Health and LLS will work together to enhance access to free care navigation and support, education, and resources for blood cancer patients, ensuring that members have access to the latest information and support services tailored to their needs.
  • "We are thrilled to join forces with The Leukemia & Lymphoma Society to better serve individuals impacted by blood cancer," said Greg Orr, COO of Jasper Health.
  • "We are excited to partner with Jasper Health to expand our reach and support for blood cancer patients," said Gina Russo, Vice President of Patient Services & Strategic Partnerships for The Leukemia & Lymphoma Society.

Bringing Light to The Darkness of Cancer: BeiGene Named National Partner of Survivorship and Hope for The Leukemia & Lymphoma Society's Light The Night

Retrieved on: 
Tuesday, March 12, 2024
Diagnosis, Research, Education, Bone marrow, Leukemia, Caregiver, Light, Partnership, Darkness, Patient, Survivor, Support, Cancer, Light the Night, RYE, LLS, BeiGene, Concurrent estate, Policy, Estate (law), Pharmaceutical industry

"BeiGene is proud to expand our partnership with the Leukemia and Lymphoma Society this year as the National Presenting Sponsor of Survivorship and Hope for Light The Night," Josh Neiman, Chief Commercial Officer at BeiGene, said.

Key Points: 
  • "BeiGene is proud to expand our partnership with the Leukemia and Lymphoma Society this year as the National Presenting Sponsor of Survivorship and Hope for Light The Night," Josh Neiman, Chief Commercial Officer at BeiGene, said.
  • "LLS's Light The Night inspires communities, bringing more people out of the darkness of cancer, shining a light on survivors everywhere.
  • BeiGene has been supporting LLS's Light The Night for the past five years, and before becoming the National Presenting Sponsor of Survivorship and Hope, was a Light The Night National Sponsor in 2022 and 2023.
  • To join Light The Night and shine a light on survivorship and hope, visit www.lightthenight.org .

Business & Community Leaders Join The Leukemia & Lymphoma Society's 2024 Visionaries Of The Year Annual Philanthropic Competition To Champion A World Without Blood Cancer

Retrieved on: 
Tuesday, March 5, 2024
Leukemia, Bone marrow, Senior, LLS, Education, Quality of life, Volunteering, Leukemia & Lymphoma Society, Patient, Policy, Research, RYE, Visionaries, Birth control

Now underway for the 35th consecutive year, business and community leaders committed to improving the lives of those impacted by blood cancer are engaging in a little healthy competition through LLS's Visionaries of the Year campaign.

Key Points: 
  • Now underway for the 35th consecutive year, business and community leaders committed to improving the lives of those impacted by blood cancer are engaging in a little healthy competition through LLS's Visionaries of the Year campaign.
  • Participants of this have 10 weeks to raise funds that will directly support LLS's life-changing work.
  • LLS recognizes these inspiring individuals as "Visionaries," who are dedicated volunteers fundraising and creating awareness about blood cancer in their communities.
  • "Together, we will find cures and improve the quality of life for all those affected and ultimately create a world without blood cancer."

Akel Homes Demonstrates Enthusiastic Support as Silver Benefactor for the 2024 LLS Black Tie Gala, Eager to Contribute to Life-Saving Cancer Research

Retrieved on: 
Friday, February 2, 2024
Multimedia, Research, LLS, Leukemia, PALM, Bone marrow, Lymphoma, Organization, Hospital

PALM BEACH, Fla., Feb. 2, 2024 /PRNewswire-PRWeb/ -- The 2024 Dare to Disco Gala was an evening of sheer elegance and excitement, with the disco-themed event bringing together philanthropists, community leaders, and supporters of all kind, creating an atmosphere of celebration and fundraising towards the fight against blood cancer.

Key Points: 
  • Akel Homes proudly announces its support to the Leukemia & Lymphoma Society (LLS) as a Silver Benefactor sponsor of this year's Dare to Disco Black Tie Gala hosted at The Breakers, Palm Beach on January 24th.
  • "We are elated to participate as the Silver Benefactor sponsor for this year's Dare to Disco Black Tie Gala," said Teresa Tigert, Director of Purchasing at Akel Homes.
  • This event provides us with an opportunity to join hands with the community in supporting groundbreaking research and life-saving treatments."
  • Akel Homes invites the community to join them in supporting the fight against leukemia and lymphoma.

Rgenta Therapeutics Joins The Leukemia & Lymphoma Society Therapy Acceleration Program®

Retrieved on: 
Tuesday, January 30, 2024
Partnership, MYB, RNA, Oncogene, Therapy, Leukemia & Lymphoma Society, Patient, LLS, Leukemia, Bone marrow, TAP, CSO

CAMBRIDGE, Mass., Jan. 30, 2024 /PRNewswire/ -- Rgenta Therapeutics ("Rgenta" or the "Company") today announced that it was selected by The Leukemia & Lymphoma Society (LLS) as a new Therapy Acceleration Program® (TAP) portfolio company, and provided with strategic funding to support preclinical and clinical advancement of the Company's therapeutics in hematologic malignancies utilizing its RNA-targeting small molecule platform to target MYB, an oncogenic transcription factor.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 30, 2024 /PRNewswire/ -- Rgenta Therapeutics ("Rgenta" or the "Company") today announced that it was selected by The Leukemia & Lymphoma Society (LLS) as a new Therapy Acceleration Program® (TAP) portfolio company, and provided with strategic funding to support preclinical and clinical advancement of the Company's therapeutics in hematologic malignancies utilizing its RNA-targeting small molecule platform to target MYB, an oncogenic transcription factor.
  • "We are honored by the support and recognition of LLS's Therapy Acceleration Program.
  • LLS's strategic investment in Rgenta continues to bolster our confidence in the potential of our pipeline of oral, small-molecule RNA-targeting medicines," commented Simon Xi, Ph.D., CEO of Rgenta.
  • "We look forward to tapping into the extensive clinical expertise and resources from LLS to accelerate the development of our RNA-targeting MYB inhibitor molecules."

Kura Oncology’s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial

Retrieved on: 
Friday, December 8, 2023
Princess, Leukemia & Lymphoma Society, Partnership, Research, Bone marrow, KURA, Drug, Kura, SAN, Pedal, Clinical trial, Cancer, LLS, Leukemia, Patient, Acute leukemia, Pharmaceutical industry

“We are honored to be designated for the PedAL initiative, marking Kura’s continued development of ziftomenib for the treatment of acute leukemias,” said Mollie Leoni, M.D., Executive Vice President, Clinical Development.

Key Points: 
  • “We are honored to be designated for the PedAL initiative, marking Kura’s continued development of ziftomenib for the treatment of acute leukemias,” said Mollie Leoni, M.D., Executive Vice President, Clinical Development.
  • “Kura remains committed to developing new treatment options across the continuum of care, including for pediatric patients with acute leukemias where poor outcomes and significant unmet medical need remain.
  • PedAL is a pioneering global master clinical trial for Pediatric Acute Leukemia, founded and led by LLS, which aims to advance more effective, safer treatments with fewer long-term side effects, for children with blood cancer.
  • Kura will supply LLS and the Princess Máxima Center with ziftomenib for the study.

LMU Names Brietta Clark, J.D., as Next Fritz B. Burns Dean of LMU Loyola Law School

Retrieved on: 
Tuesday, December 19, 2023
LMU, Faculty, American Journal, Bioethics, Student, Research, Health law, Trustee, Social justice, Education, LLS, University, Loyola Marymount University, Publication, Public health, Nursing

LOS ANGELES, Dec. 19, 2023 /PRNewswire/ -- In a historic move, Loyola Marymount University (LMU) announced that it has appointed Brietta Clark, J.D., as the new Fritz B. Burns Dean of LMU Loyola Law School. This makes Clark, who is the 19th dean of the law school, the first woman to hold the position and also the first Black dean in the law school's history. Dean Clark has served as interim dean since July 16, 2023.

Key Points: 
  • LOS ANGELES, Dec. 19, 2023 /PRNewswire/ -- In a historic move, Loyola Marymount University (LMU) announced that it has appointed Brietta Clark, J.D., as the new Fritz B. Burns Dean of LMU Loyola Law School.
  • This makes Clark, who is the 19th dean of the law school, the first woman to hold the position and also the first Black dean in the law school's history.
  • Since joining the law school faculty in 2001, Clark has been instrumental in developing and implementing the law school's strategic vision.
  • During her tenure, she has served in numerous leadership roles in addition to interim dean, including associate dean for faculty from 2015-20.

Vittoria Biotherapeutics Secures Over $15 Million in Private Financing Round to Support the Development of Novel CAR-T Cell Therapies

Retrieved on: 
Tuesday, November 14, 2023
Safety, Engineering, Hope, Leukemia & Lymphoma Society, University, Stem cell, Leukemia, New York Blood Center, Investment, Patient, T-cell lymphoma, Genetic engineering, CD5, Joseph Vittoria, Cancer, Lymphoma, LLS, Pharmaceutical industry

PHILADELPHIA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics today announced it has secured over $15 million in a private financing round.

Key Points: 
  • PHILADELPHIA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics today announced it has secured over $15 million in a private financing round.
  • The funds will be used to continue advancing Vittoria’s lead candidate, VIPER-101, an autologous, dual population CD5-knockout CAR-T cell therapy for T-cell Lymphoma, into the clinic.
  • The additional capital will support Vittoria’s clinical development initiatives and advance its next-generation cell therapies that strengthen efficacy, improve safety, and broaden therapeutic applicability for patients with cancer and autoimmune diseases.
  • By acting on the fundamental biology of T cells, Senza5 can be widely utilized to improve the efficacy of engineered T-cell therapies.